Live Breaking News & Updates on Apremilast

Stay informed with the latest breaking news from Apremilast on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Apremilast and stay connected to the pulse of your community

Approaching Plaque Psoriasis Treatment in Difficult-to-Treat Areas

An expert in dermatology provides insight on approaching treatment in patients with plaque psoriasis who have a low BSA involvement, but with symptoms that present in difficult-to-treat areas.

Aprilw-armstrong , Board-of-the-national-psoriasis-foundation , Chair-emeritus , Medical-board , National-psoriasis , Difficult-to-treat-areas , Plaque-psoriasis-treatment , Low-bsa-involvement , Payer , Oral-medication , Apremilast

Head-to-Head Studies for Plaque Psoriasis Therapies

Expert dermatologists highlight the benefits of head-to-head trials for various agents for the management of plaque psoriasis and review the top-line results of a study comparing risankizumab and apremilast.

Benjamin-lockshin , Andy-blauvelt , Bruce-strober , Jennifer-soung , Plaque-psoriasis , Head-to-studies , Skin-clearance-rates , Il-23-inhibitors , Meta-analysis , Cumulative-effect , Durability

Low Apremilast Persistence May Hinder Remission, Recovery Among Patients with PsA

Results demonstrated a low persistence rate for apremilast among patients with PsA, highlighting a notable barrier to treatment success.

Israel , Israeli , Amir-haddad , Carmel-medical-center , Israeli-national-healthcare-drug-plan , Clalit-health-services , National-psoriasis-foundation , Israeli-national-healthcare-drug , Apremilast-among-patients , About-psoriatic , Accessed-october , Psa

Comparing 2 Oral Therapies in Plaque Psoriasis

Jayme Heim, MSN, FNP-BC, compares the efficacy, safety and dosing of 2 oral therapies, apremilast and deucravacitinib, for the treatment of plaque psoriasis.

Jayme-heim , Lauren-miller , Plaque-psoriasis , Pp , Apremilast , Deucravacitinib , Comparing-safety-and-efficacy , Tyk2-inhibitor , Gi-adverse-effect ,

Advances in Oral Therapies in Plaque Psoriasis

Jayme Heim, MSN, FNP-BC; and Lauren Miller, MPAS, PA-C, share thoughts on the use of oral systemic and biologic treatments in plaque psoriasis, commenting on the need for personalized care for patients.

Jayme-heim , Lauren-miller , Plaque-psoriasis , Pp , Advanced-practice-providers , Delay-in-topical-therapies , Pasi , Partial-response , Deucravacitinib , Oral-therapy , Apremilast

Risankizumab Shown to be Superior to Apremilast in Treating Adults with Moderate Psoriasis

This new phase 4 data provides some valuable insights for healthcare professionals and those seeking to compare therapy options for psoriasis.

United-kingdom , British , Lindaf-stein , Psoriasis-area , Severity-index , Static-physician , Global-assessment , Linda-stein-gold , Body-surface-area , Treatment-satisfaction-questionnaire , Achieved-superiority-versus-apremilast

Benchmarks turn range bound; VIX spurts 7%

Benchmark indices traded in a narrow range with modest losses in early afternoon trade. Resurgent worries about rising US bond yields hit global shares. The Nifty continued to hover around the 15,000 mark.
At 12:22 IST, the barometer index, the S&P BSE Sensex, was down 196.97 points or 0.39% at 50,649.20. The Nifty 50 index fell 70.45 points or 0.47% at 15,010.60.
In broader market, the S&P BSE Mid-Cap index was down 1.27% while the S&P BSE Small-Cap index was down 0.76%.
The market breadth turned negative. On the BSE, 1151 shares rose and 1590 shares fell. A total of 145 shares were unchanged.
COVID-19 Update:
Total COVID-19 confirmed cases worldwide stood at 115,597,805 with 25,69,011 deaths. India reported 176,319 active cases of COVID-19 infection and 157,548 deaths while 108,39,894 patients have been discharged, according to the data from the Ministry of Health and Family Welfare, Government of India.

India , Baroda , Gujarat , Mysuru , Karnataka , United-states , Sri-lanka , Bandhan-bank , Bank-nifty , Drug-administration , Ministry-of-health

Shilpa Medicare gets USFDA nod for arthritis drug

Shilpa Medicare has received United States Food and Drug Administration (USFDA)'s tentative approval for its abbreviated new drug application (ANDA), apremilast tablets, 10 mg, 20 mg, and 30 mg.
The ANDA was filed as 'First to File' submission on NCE -1 date to seek eligibility for 180 days exclusivity.
Apremilast tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene, used in the treatment of 'psoriatic arthritis' as recommended in the label approved by FDA.
According to IQVIA MAT Q2 2020 data, the US market for apremilast tablets, 10 mg, 20 mg, and 30 mg is approximately US $2.4 billion.
Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.

United-states , Drug-administration , Shilpa-medicare , United-states-food , Capital-market , Branches-of-biology , Drugs , Biology , Phthalimides , Pharmaceutical-industry , Acetamides

Unichem Labs spurts on USFDA nod for psoriasis drug

Unichem Laboratories surged 5.71% to Rs 323.05 after the company received United States Food and Drug Administration (USFDA) approval for apremilast tablets, 10 mg, 20 mg and 30 mg.
The drug is a generic version of Amgen's Otezla (apremilast) tablets, 10 mg, 20 mg, and 30 mg.
The drug is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
The scrip extended gains for third day. The stock has added 6.67% in three sessions from its recent closing low of Rs 302.85 recorded on 16 February 2021.
In the past three months, the stock has added 36.73% while the benchmark Sensex has added 17.55% during the same period.

United-states , Amgen-otezla , Drug-administration , Unichem-laboratories , United-states-food , Capital-market , Drugs , Branches-of-biology , Apremilast , Mg-cars , Medroxyprogesterone-acetate , Magnesium-in-biology

Detailed text transcripts for TV channel - CNN - 20180122:07:19:00

don't use if you're allergic to otezla. otezla may cause severe diarrhea, nausea, or vomiting. tell your doctor if these occur. otezla is associated with an increased... ...risk of depression. tell your doctor if you have... ...a history of depression... ...or suicidal thoughts,... ...or if these feelings develop. some people taking otezla... ...reported weight loss. your doctor should monitor your weight and may stop treatment. other side effects include upper... ...respiratory tract infection and headache. tell your doctor about all the medicines you take... ...and if you're pregnant or planning to be. ask your dermatologist about otezla today. otezla. show more of you. you won't see these folks they have businesses to run. they have passions to pursue. how do they avoid trips to the post office?

Doctor , Trouble-breathing , Don-t , Thoughts , Vomiting , Nausea , History , Risk , Diarrhea , Apremilast , People , Side-effects